Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amphetamine ER Tablets in Adult ADHD
NCT03834766Phase 3Completed
- Sponsor
- Tris Pharma
- Start
- Feb 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amphetamine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Tris Pharma. Primary endpoint: Permanent Product Measure of Performance Total Score. Started Feb 2019; status: completed.
02
Drugs
amphetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03834766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834766.